{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:12:03Z","timestamp":1792761123199,"version":"4.5.0"},"reference-count":120,"publisher":"Wiley","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022110026"],"award-info":[{"award-number":["10140022110026"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:p>\n                    While the event\u2010free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding\n                    <jats:italic>histone\u2010lysine N\u2010methyltransferase 2A<\/jats:italic>\n                    (\n                    <jats:italic>KMT2A<\/jats:italic>\n                    ), whose EFS is under 40%. To improve the EFS of infants treated for ALL, it is crucial to implement optimal dosing guidelines tailored to this population. The pharmacokinetics (PK) of chemotherapeutics in infants is complex due to rapid physiological development in the first year of life. Current dosing guidelines are often extrapolated from paediatric or adult standards using body surface area or age\u2010based adjustments. This may not adequately account for the unique PK\u2010characteristics of infants since developmental changes will influence the absorption, distribution, metabolism, and elimination of chemotherapeutics. In this review, we will provide a comprehensive overview of how developmental changes could affect the PK of chemotherapeutics used in the treatment of ALL. Key factors we evaluated are renal maturation, body composition, blood composition and ontogeny of drug\u2010metabolizing enzymes and transporters. Understanding the influence of developmental processes taking place in the first year of life on the PK of chemotherapeutics will aid the eventual application of evidence\u2010based dosing guidelines tailored specifically to infants treated for ALL, making it possible to determine more appropriate starting doses for each stage of development. These tailored dosing guidelines will enhance the precision and safety of chemotherapy in this vulnerable population.\n                  <\/jats:p>","DOI":"10.1002\/bcp.70317","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:29:46Z","timestamp":1761532186000},"source":"Crossref","is-referenced-by-count":3,"title":["Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia\u2014A comprehensive review"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6057-6883","authenticated-orcid":false,"given":"Tirsa","family":"de Kluis","sequence":"first","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiah J.","family":"Brigitha","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwien M.","family":"Hanff","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"},{"name":"University Medical Center Utrecht  Utrecht The Netherlands"},{"name":"Netherlands Cancer Institute  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meta H. M.","family":"Diekstra","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02705"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201012\u2010322909"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01086"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u201001024\u20100"},{"issue":"3","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201045 years with acute lymphoblastic leukemia","volume":"32","author":"Toft N","year":"2018","journal-title":"Leukemia"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01692"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00261"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201003\u2010273532"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010006\u20100388\u20101"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25322"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(07)61126\u2010X"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201007\u20103011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214171"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004741"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.001"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"issue":"11","key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":"Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations","volume":"45","author":"Bartelink I","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/jcph.1284","article-title":"Developmental changes in pharmacokinetics and pharmacodynamics","volume":"58","author":"Van den Anker J","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2013.10.008"},{"issue":"2","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/B:UROL.0000034681.60457.84","article-title":"Renal physiology in newborns and old people: similar characteristics but different mechanisms","volume":"36","author":"Musso C","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15557"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14821"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"issue":"6","key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-024-04713-0","article-title":"Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination","volume":"94","author":"Rex S","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.05.079"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253074"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018609031233"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02985158"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018909034276"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880010600796095"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7579"},{"issue":"2","key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00228-004-0732-5","article-title":"Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age","volume":"60","author":"Ganiere\u2010Monteil C","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201005\u2010024414"},{"issue":"1","key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00007691-199101000-00004","article-title":"Fat body mass and pharmacokinetics of oral 6\u2010mercaptopurine in children with acute lymphoblastic leukemia","volume":"13","author":"Zuccaro P","year":"1991","journal-title":"Ther Drug Monit"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090563"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010024\u201003693\u20103"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201038983\u20100"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030272"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29203"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201005\u20101600"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010014\u20102535\u20104"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010001\u20100392\u20104"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010008\u20100854\u2010z"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221117810"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22266"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010002\u20100554\u2010z"},{"key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2024.1416440","article-title":"Getting the dose right using physiologically\u2010based pharmacokinetic modeling: dexamethasone to prevent post\u2010extubation stridor in children as proof of concept","volume":"12","author":"Van der Heijden J","year":"2024","journal-title":"Front Pediatr"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8404"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201010\u2010311969"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.03.026"},{"issue":"8201","key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0140-6736(80)92105-4","article-title":"Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?","volume":"2","author":"Pinkerton C","year":"1980","journal-title":"Lancet"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050405"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.45"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402373"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1799"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010016\u20103008\u20108"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1613537"},{"issue":"14","key":"e_1_2_8_61_1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.23.01797","article-title":"Continuous PEGasparaginase dosing reduces hypersensitivity reactions in pediatric ALL: a Dutch childhood oncology group ALL11 randomized trial","volume":"42","author":"Van der Sluis I","year":"2024","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019609030855"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26139"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00217"},{"issue":"3","key":"e_1_2_8_65_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.12886","article-title":"Associations of novel genetic variations in the folate\u2010related and ARID5B genes with the pharmacokinetics and toxicity of high\u2010dose methotrexate in paediatric acute lymphoblastic leukaemia","volume":"166","author":"Csordas K","year":"2014","journal-title":"Br J Haematol"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00307"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4156"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201001\u2010480335"},{"key":"e_1_2_8_69_1","first-page":"919","article-title":"The role of single nucleotide polymorphisms in transporter proteins and the folate metabolism pathway in delayed methotrexate excretion: a case report and literature review","volume":"15","author":"Wang J","year":"2022","journal-title":"Pharmacogenomics Pers Med"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2019.1705949"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11040468"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.01.004"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201008\u2010452839"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2022.2069060"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010011\u20101046\u2010z"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12453"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010022\u201003364\u20101"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.05.007"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1179"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.81"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14596"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010011\u20101745\u20102"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010010\u20101541\u20104"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440\u20101754.2011.02103.x"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22845"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26854"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31160"},{"issue":"2","key":"e_1_2_8_88_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.leukres.2009.04.027","article-title":"Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia","volume":"34","author":"Hartman A","year":"2010","journal-title":"Leuk Res"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010024\u201003677\u20103"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001591\u20104"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30154\u20107"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201038414\u20100"},{"issue":"3","key":"e_1_2_8_93_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2016.149195","article-title":"Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients","volume":"102","author":"Sassen S","year":"2017","journal-title":"Haematologica"},{"issue":"36","key":"e_1_2_8_94_1","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg A","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010019\u201000823\u20108"},{"key":"e_1_2_8_96_1","unstructured":"Blinatumomab.Annex I: Summary of product characteristics.2024;30."},{"key":"e_1_2_8_97_1","unstructured":"Cyclophosphamide. DrugBank. Accessed January 28 2025.https:\/\/go.drugbank.com\/drugs\/DB00531"},{"key":"e_1_2_8_98_1","unstructured":"Cyclophosphamide. Accessed January 28 2025.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553087"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201019\u20102685"},{"key":"e_1_2_8_100_1","unstructured":"Cytarabine. Accessed January 28 2025.https:\/\/go.drugbank.com\/drugs\/DB00987"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050536"},{"issue":"18","key":"e_1_2_8_102_1","article-title":"Disposition of antineoplastic agents in the very young child","volume":"66","author":"McLeod H","year":"1992","journal-title":"Br J Cancer"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401129"},{"issue":"3","key":"e_1_2_8_104_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.leu.2403253","article-title":"In vitro drug\u2010resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype","volume":"18","author":"Ramakers\u2010van Woerden N","year":"2004","journal-title":"Leukemia"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986709788803312"},{"key":"e_1_2_8_106_1","unstructured":"Doxorubicin. Accessed January 28 2025.https:\/\/go.drugbank.com\/drugs\/DB00997"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100272\u20104"},{"issue":"6","key":"e_1_2_8_108_1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00280-016-3174-8","article-title":"Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a \u201cEuropean Pediatric Oncology Off\u2010patents Medicines Consortium\u201d trial","volume":"78","author":"Krischke M","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010017\u20103309\u20106"},{"issue":"1","key":"e_1_2_8_110_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-020-00417-2","article-title":"Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure","volume":"21","author":"Siebel C","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"e_1_2_8_111_1","unstructured":"Dexamethasone. PubChem [Internet]. Accessed January 28 2025.https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/dexamethasone"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201009\u2010381731"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010023\u201003544\u20107"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13600"},{"issue":"4","key":"e_1_2_8_115_1","first-page":"1","article-title":"High\u2010dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: a population pharmacokinetic study","volume":"64","author":"Chen X","year":"2024","journal-title":"Br J Haematol"},{"key":"e_1_2_8_116_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine\u2010induced peripheral neuropathy in children with cancer: a systematic review","volume":"114","author":"Van de Velde M","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"e_1_2_8_117_1","unstructured":"Vincristine. DrugBank [Internet]. Accessed January 28 2025.https:\/\/go.drugbank.com\/drugs\/DB00541"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010023\u201001336\u20101"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.014"},{"key":"e_1_2_8_120_1","unstructured":"PATIO study: pharmacokinetic study on anticancer treatment in infant acute lymphoblastic leukemia to support optimal dosing [Internet]. Accessed January 31 2025.https:\/\/projecten.zonmw.nl\/nl\/project\/patio-study-pharmacokinetic-study-anticancer-treatment-infant-acute-lymphoblastic-leukemia"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010023\u201003598\u2010x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:29:50Z","timestamp":1761532190000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":120,"alternative-id":["10.1002\/bcp.70317"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70317","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]},"article-number":"bcp.70317"}}